Drugs / ETH-155008
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05758610 | Nov 2022 → Dec 2025 | acute myeloid leukemia, non-Hodgkin lymphoma | Shengke Pharmaceuticals (Jiangsu) Limited, China | Unknown | No outcome recorded |
| Phase 1 | NCT04840784 | Jun 2021 → May 2023 | leukemia, non-Hodgkin lymphoma | Shengke Pharmaceuticals Pty Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETH-155008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04840784 ↗ |
| Action | Inhibit | “ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.” NCT04840784 ↗ |
| Route | Oral | “ETH-155008 will be administrated orally” NCT04840784 ↗ |
| Target | CDK4 | “ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.” NCT04840784 ↗ |